The prevalence and clinical correlates of metabolic syndrome in patients with schizophrenia: Findings from a cohort in Turkey

European Archives of Psychiatry and Clinical Neuroscience

Volumn 261, Issue 1, 2011, Pages 69-78

  Yazici M K ^a   Anil Yagcioglu A E ^a   Ertugrul A ^a   Eni, N ^a   Karahan, S ^a   Karaagaoglu E ^a   Tokgozoglu S L ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Cardiovascular risk; Correlates; Metabolic syndrome; Prevalence; Schizophrenia

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PREVALENCE; PRIORITY JOURNAL; SCHIZOPHRENIA; TURKEY (REPUBLIC);

EID: 79951853672     PISSN: 09401334     EISSN: 14338491     Source Type: Journal    
DOI: 10.1007/s00406-010-0118-x     Document Type: Article

References (50)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults 2001 Executive summary of the third report of the National Cholesterol education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) JAMA 285 2486 2497 10.1001/jama.285.19.2486
2. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus 2003 Follow-up report on the diagnosis of diabetes mellitus Diabetes Care 26 3160 3166 10.2337/diacare.26.11.3160 (Pubitemid 37339514)
3. SM Grundy B Brewer JL Cleeman SC Smith C Lenfant 2004 Definition of metabolic syndrome: report of the National Heart, Lung, And Blood Institute/American Heart Association Conference on scientific issues related to definition Circulation 109 433 438 10.1161/01.CIR.0000111245.75752.C6 14744958 (Pubitemid 38133916)
4. IDF (2005) The IDF Consensus Worldwide Definition of the Metabolic Syndrome. International Diabetes Federation, Brussels
5. J Suvisaari J Perälä SI Saarni T Härkänen S Pirkola M Joukamaa S Koskinen J Lönnqvist A Reunanen 2008 Type 2 diabetes among persons with schizophrenia and other psychotic disorders in a general population survey Eur Arch Psychiatry Clin Neurosci 258 129 136 10.1007/s00406-007-0762-y 17990051 (Pubitemid 351642149)
6. AH Barnett HL Millar JY Loze GJ L'Italien M van Baardewijk M Knapp 2009 UK cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (STAR study) Eur Arch Psychiatry Clin Neurosci 259 239 247 10.1007/s00406-008-0863-2 19267255
7. S Leucht 2009 Physical illness and schizophrenia Eur Arch Psychiatry Clin Neurosci 259 Suppl 1 S34
8. T Heiskanen L Niskanen R Lyytikainen PI Saarinen J Hintikka 2003 Metabolic syndrome in patients with schizophrenia J Clin Psychiatry 64 575 579 10.4088/JCP.v64n0513 12755662 (Pubitemid 36618288)
9. Littrell KH, Petty R, Ortega TR, Moore D, Ballard A, Clough R, Lan TS, Selby C (2003) Insulin resistance and Syndrome X among patients with schizophrenia. Abstract presented at the American Psychiatric Association Annual Meeting, San Francisco
10. MM Kato MB Currier CM Gomez L Hall M Gonzalez-Blanco 2004 Prevalence of metabolic syndrome in Hispanic and non-Hispanic patients with schizophrenia Prim Care Companion J Clin Psychiatry 6 74 77 10.4088/PCC.v06n0205 15254600
11. R Basu JS Brar KNR Chengappa V John H Parapally S Gershon P Schlicht D Kupfer 2004 The prevalence of the metabolic syndrome in patients with schizoaffective disorder-bipolar subtype Bipolar Disord 6 314 318 10.1111/j.1399-5618.2004.00126.x 15225149 (Pubitemid 39077092)
12. T Cohn D Prud'homme D Streiner H Kameh G Remington 2004 Characterizing coronary heart disease risk in schizophrenia: high prevalence of the metabolic syndrome Can J Psychiatry 49 753 760 15633853 (Pubitemid 40094948)
13. JM Meyer G Pandina CA Bossie I Turkoz A Greenspan 2005 Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study Clin Ther 27 1930 1941 1:CAS:528:DC%2BD28XhsVemsrs%3D 10.1016/j.clinthera.2005.12.005 16507379 (Pubitemid 43293215)
14. KM Saari SM Lindeman KM Viilo MK Isohanni M-R Jarvelin LH Lauren MJ Savolainen HJ Koponen 2005 A 4-fold risk of metabolic syndrome in patients with schizophrenia: the northern Finland 1966 birth cohort study J Clin Psychiatry 66 559 563 10.4088/JCP.v66n0503 15889940 (Pubitemid 40733696)
15. Koponen HJ, Hakko HH, Saari KM, Lindeman SM, Karvonen KM, Isohanni MK, Lauren LH, Savolainen MJ, Jarvelin MR (2008) The prevalence and predictive value of individual criteria for metabolic syndrome in schizophrenia: a Northern Finland 1966 Birth Cohort Study. World J Biol Psychiatry 1-6
16. JP McEvoy JM Meyer DC Goff HA Nasrallah SM Davis L Sullivan HY Meltzer J Hsiao TS Stroup JA Lieberman 2005 Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the clinical antipsychotic trial and comparison with national estimates from NHANES III Schizophr Res 80 19 32 10.1016/j.schres.2005.07.014 16137860 (Pubitemid 41587460)
17. S Hagg Y Lindblom T Mjorndal R Adolfsson 2006 High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia Int Clin Psychopharmacol 21 93 98 10.1097/01.yic.0000188215.84784.17 16421460 (Pubitemid 43740316)
18. JM Meyer C Loh SG Leckband JA Boyd WC Wirshing JM Pierre D Wirshing 2006 Prevalence of the metabolic syndrome in veterans with schizophrenia J Psychiatr Pract 12 5 10 10.1097/00131746-200601000-00002 16432440 (Pubitemid 44378042)
19. CU Correll AM Frederickson JM Kane P Manu 2006 Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs J Clin Psychiatry 67 575 583 1:CAS:528:DC%2BD28XlsVegsbY%3D 10.4088/JCP.v67n0408 16669722 (Pubitemid 43764234)
20. JS Lamberti D Olson JF Crilly T Olivares GC Williams X Tu W Tang K Wiener S Dvorin MB Dietz 2006 Prevalence of the metabolic syndrome among patients receiving clozapine Am J Psychiatry 163 1273 1276 10.1176/appi.ajp.163.7.1273 16816234 (Pubitemid 44464457)
21. M De Hert R van Winkel D Van Eyck L Hanssens M Wampers A Scheen J Peuskens 2006 Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication Schizophr Res 83 87 93 10.1016/j.schres.2005.12.855 16481149
22. PJ Teixeira FL Rocha 2007 The prevalence of metabolic syndrome among psychiatric inpatients in Brazil Rev Bras Psiquiatr 29 330 336 10.1590/S1516-44462007000400007 18200397 (Pubitemid 351358057)
23. T Sanchez-Arana Moreno R Tourino Gonzalez JL Hernandez Fleta P Leon Perez 2007 Prevalence of the metabolic syndrome among schizophrenic patients hospitalized in the Canary Islands Actas Esp Psiquiatr 35 359 367 1:STN:280:DC%2BD2snotVWhtw%3D%3D 18004674
24. S Tirupati LE Chua 2007 Body mass index as a screening test for metabolic syndrome in schizophrenia and schizoaffective disorders Australas Psychiatry 15 470 473 10.1080/10398560701636906 17999257 (Pubitemid 350120843)
25. Srisurapanont M, Likhitsathian S, Boonyanaruthee V, Charnsilp C, Jarusuraisin N (2007) Metabolic syndrome in Thai schizophrenic patients: a naturalistic one-year follow-up study. BMC Psychiatry 7:14
26. E Kurt K Altinbas G Alatas İ Ozver 2007 Metabolic syndrome prevalence among schizophrenic patients treated in chronic inpatient clinics Psychiatry in Türkiye 3 141 145
27. J Bobes C Arango P Aranda R Carmena M Garcia-Garcia J Rejas CLAMORS Study Collaborative Group 2007 Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS study Schizophr Res 90 162 173 10.1016/j.schres.2006.09.025 17123783 (Pubitemid 46177553)
28. Rejas J, Bobes J, Arango C, Aranda P, Carmena R, Garcia-Garcia M (2008) Concordance of standard and modified NCEP ATP III criteria for identification of metabolic syndrome in outpatients with schizophrenia treated with antipsychotics: a corollary from the CLAMORS study. Schizophr Res 99:23-28, 26
29. S Saddichha N Manjunatha S Ameen S Akhtar 2008 Metabolic syndrome in first episode schizophrenia-a randomized double-blind controlled, short-term prospective study Schizophr Res 101 266 272 10.1016/j.schres.2008.01.004 18262771
30. CU Correll AM Frederickson JM Kane P Manu 2008 Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics Bipolar Disord 10 788 797 10.1111/j.1399-5618.2008.00625.x 19032710
31. C Cerit E Ozten M Yildiz 2008 The prevalence of metabolic syndrome and related factors in patients with schizophrenia Turk Psikiyatri Derg 19 124 132 18561044
32. O Boke S Aker G Sarisoy EB Saricicek AR Sahin 2008 Prevalence of metabolic syndrome among inpatients with schizophrenia Int J Psychiatry Med 38 103 112 10.2190/PM.38.1.j 18624022
33. DG Oyekcin 2009 The frequency of metabolic syndrome in patients with schizophrenia and schizoaffective disorder Anatolian J Psychiatry 10 26 33
34. MC Kaya O Virit A AltIndaǧ S Selek F Bülbül M Bulut HA Savaş 2009 Prevalence of metabolic syndrome, characteristics of metabolic syndrome and relationship with the antipsychotics used in schizophrenia Arch Neuropsychiatry 46 13 18
35. S Brunero S Lamont G Fairbrother 2009 Prevalence and predictors of metabolic syndrome among patients attending an outpatient clozapine clinic in Australia Arch Psychiatr Nurs 23 261 268 10.1016/j.apnu.2008.06.007 19446781
36. MC Huang ML Lu CJ Tsai PY Chen CC Chiu DL Jian KM Lin CH Chen 2009 Prevalence of metabolic syndrome among patients with schizophrenia or schizoaffective disorder in Taiwan Acta Psychiatr Scand 120 274 280 10.1111/j.1600-0447.2009.01401.x 19426161
37. DC Goff LM Sullivan JP McEvoy JM Meyer HA Nasrallah GL Daumit S Lamberti RB D'Agastino TS Stroup S Davis JA Lieberman 2005 A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls Schizophr Res 80 45 53 10.1016/j.schres.2005.08.010 16198088 (Pubitemid 41587462)
38. Arango C, Bobes J, Aranda P, Carmena R, Garcia-Garcia M, Rejas J; on behalf of the CLAMORS study collaborative group (2008) A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: findings from the CLAMORS study. Schizophr Res 104:1-12
39. O Kozan A Oguz A Abaci C Erol Z Ongen A Temizhan S Celik 2007 Prevalence of the metabolic syndrome among Turkish adults Eur J Clin Nutr 61 548 553 1:STN:280:DC%2BD2s3gt1ehtw%3D%3D 17119546 (Pubitemid 46605227)
40. PW Wilson RB D'Agostino D Levy AM Belanger H Silbershatz WB Kannel 1998 Prediction of coronary heart disease using risk factor categories Circulation 97 1837 1847 1:STN:280:DyaK1c3msVOjsA%3D%3D 9603539 (Pubitemid 28213628)
41. A Onat V Sansoy 2002 Metabolic syndrome, major culprit of coronary disease among Turks: its prevalence and impact on coronary risk Türk Kardiyol Dern Arş 30 8 15
42. D Straker CU Correll E Kramer-Ginsberg N Abdulhamid F Koshy E Rubens R Saint-Vil JM Kane P Manu 2005 Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications Am J Psychiatry 162 1217 1221 10.1176/appi.ajp.162.6.1217 15930076 (Pubitemid 40770711)
43. M De Hert V Schreurs D Vancampfort RD Van Winkel 2009 Metabolic syndrome in people with schizophrenia: a review World Psychiatry 8 15 22
44. M De Hert JM Dekker D Wood KG Kahl RIG Holt HJ Möller 2009 Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC) Eur Psychiatry 24 412 424 10.1016/j.eurpsy.2009.01. 005 19682863
45. DW Haupt 2006 Differential metabolic effects of antipsychotic treatments Eur Neuropsychopharmacol 16 S149 S155 1:CAS:528:DC%2BD28XotVyrsrg%3D 10.1016/j.euroneuro.2006.06.003 16872808 (Pubitemid 44175821)
46. M De Hert V Schreurs K Sweers D Van Eyck L Hanssens S Sinko M Wampers A Scheen J Peuskens R van Winkel 2008 Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review Schizophr Res 101 295 303 10.1016/j.schres.2008.01.028 18299188
47. JM Meyer VG Davis DC Goff JP McEvoy HA Nasrallah SM Davis RA Rosenheck GL Daumit J Hsiao MS Swartz TS Stroup JA Lieberman 2008 Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1 Schizophr Res 101 273 286 10.1016/j.schres.2007.12.487 18258416
48. SM Stahl L Mignon JM Meyer 2009 Which comes first: atypical antipsychotics treatment or cardiometabolic risk? Acta Psychiatr Scand 119 171 179 1:CAS:528:DC%2BD1MXjvVKmsrY%3D 10.1111/j.1600-0447.2008.01334.x 19178394
49. V Simon R van Winkel M De Hert 2009 Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review J Clin Psychiatry 70 1041 1050 1:CAS:528:DC%2BD1MXhsFentbnK 10.4088/JCP.08r04392 19653979
50. RA Bermudes PE Keck Jr JA Welge 2006 The prevalence of the metabolic syndrome in psychiatric inpatients with primary psychotic and mood disorders Psychosomatics 47 491 497 10.1176/appi.psy.47.6.491 17116950 (Pubitemid 44657599)